Quantum Biopharma Ltd. Class B Subordinate Voting Shares (QNTM)
Stock · NASDAQ · Health Care
$2.48as of 10/16/2026
Price chart
Active signals
QNTM Signal Track Record
How signals performed across all stocks →What QNTM's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 22 | -4.4% | 45% | September 23, 2026 |
| Bollinger Band Breakout | 22 | -10.5% | 36% | August 14, 2026 |
| Bollinger Band Breakdown | 18 | +1.0% | 50% | July 22, 2026 |
| 200-Day Moving Average TouchActive now | 15 | -3.1% | 47% | May 22, 2026 |
| Any 20-session window (baseline) | -6.4% | 40% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About QNTM
Quantum BioPharma Ltd., together with its subsidiaries, operates as a biopharmaceutical company. The company operates through two segments, Biopharmaceutical Innovation and Strategic Investments. It researches and develops a portfolio of assets and biotech solutions for the treatment of neurodegenerative, inflammatory and metabolic disorders, and alcohol misuse disorders with drug candidates in different stages of de…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Website
- www.quantumbiopharma.com/
Fundamentals
- 1-day range
- $2.46$2.75
- Market cap
- $20.67M
- P/E (trailing)
- —
- P/E (forward)
- -0.32
- EPS (trailing)
- $-5.70
- Dividend yield
- —
- Beta
- 5.51
- Avg. volume
- 210.2K
Forecasts
1 analyst ratings
Quantum Biopharma Ltd. Class B Subordinate Voting Shares Competitors
Chosen by industry and closest market cap.
- QNTMQuantum Biopharma Ltd. Class B Subordinate Voting Shares$2.47▼ 8.86%Market cap $20.67MP/E —$2.85$23.1
- ATOSAtossa Therapeutics Inc. Common Stock$2.91▲ 9.81%Market cap $20.84MP/E —$1.7$16.5
- NEUPNeuphoria Therapeutics Inc. Common Stock$3.3▼ 0.30%Market cap $21.08MP/E —$3.19$17.9
- NXTCNextCure Inc. Common Stock$6.24▼ 9.30%Market cap $20.19MP/E —$1.55$15.74
- CLRBCellectar Biosciences Inc. Common Stock$1.14▼ 4.20%Market cap $20.14MP/E —$1.15$5.07
- DAREDare Bioscience Inc. Common Stock$0.725▼ 2.03%Market cap $19.92MP/E —$0.69$3.78
- GRDXGridAI Technologies Corp. Common Stock$4.22▼ 5.38%Market cap $19.91MP/E —$1.87$6.93
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| QNTM Quantum Biopharma Ltd. Class B Subordinate Voting Shares | $20.67M | — | $2.47 | ▼ 8.86% | $2.85$23.1 |
| ATOS Atossa Therapeutics Inc. Common Stock | $20.84M | — | $2.91 | ▲ 9.81% | $1.7$16.5 |
| NEUP Neuphoria Therapeutics Inc. Common Stock | $21.08M | — | $3.3 | ▼ 0.30% | $3.19$17.9 |
| NXTC NextCure Inc. Common Stock | $20.19M | — | $6.24 | ▼ 9.30% | $1.55$15.74 |
| CLRB Cellectar Biosciences Inc. Common Stock | $20.14M | — | $1.14 | ▼ 4.20% | $1.15$5.07 |
| DARE Dare Bioscience Inc. Common Stock | $19.92M | — | $0.725 | ▼ 2.03% | $0.69$3.78 |
| GRDX GridAI Technologies Corp. Common Stock | $19.91M | — | $4.22 | ▼ 5.38% | $1.87$6.93 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Why Thermo Fisher Scientific (TMO) Is Back In The SpotlightYahoo · 10/8/2026
- World Renowned Law Firm Grant & Eisenhofer Appointed Lead Counsel In Newly Consolidated Class Action Lawsuit Against Canadian Banks CIBC and RBC Alleging Illegal Stock Market Manipulation of Quantum BioPharma SharesYahoo · 10/8/2026
- Quantum BioPharma (QNTM) Enlists Thermo Fisher's Clinical Research Business to Launch Phase 2 Lucid-MS TrialYahoo · 10/7/2026
- Quantum BioPharma (QNTM) Enters Study Start-Up Agreement for Lucid-MS Phase 2 TrialYahoo · 10/6/2026
- Quantum BioPharma Signs Contract with Thermo Fisher Scientific’s Clinical Research Business to Implement Phase 2 Lucid-MS Trial in Multiple SclerosisYahoo · 10/6/2026
- EXCLUSIVE: Thermo Fisher To Support Quantum Biopharma in Progressive Multiple Sclerosis Drug TrialYahoo · 10/6/2026
- Shares of lifesciences and medical equipment stocks are trading higher following strong earnings from Sartorius.Benzinga · 10/6/2026
- IBN Announces Latest Episode of The BioMedWire Podcast Featuring the Return of Anthony Durkacz, Executive Co-Chair of Quantum BioPharma Ltd.Yahoo · 9/30/2026
Institutional Ownership
March 31, 2026
- Total shares held
- 254.3K
- Total value held
- $1.17M
- Institutional holders
- 25
- Unknown108.6K
- Unknown41.1K
- Unknown31.5K
- Unknown15.9K
- Unknown13.5K
- Unknown12.3K
- Unknown10.1K
- Unknown7.2K
- Unknown6.4K
- Unknown4.4K
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 1, 2026
Quantum Biopharma Advances Lucid-MS to Phase 2 and Expands Leadership
Quantum Biopharma received FDA approval to advance its Lucid-MS program into phase 2 testing, marking a key milestone for the company’s multiple sclerosis portfolio. The company also highlighted its leadership in a recent BioMedWire podcast where Anthony Durkacz, the executive co‑chair, discussed strategic priorities. Additionally, its licensee Unbuzzd Wellness announced a new CEO, Michael Zapolin, as it moves forward with an alcohol metabolism accelerant.
Quantum Biopharma Advances Lucid-MS to Phase 2 and Expands Leadership. Quantum Biopharma received FDA approval to advance its Lucid-MS program into phase 2 testing, marking a key milestone for the company’s multiple sclerosis portfolio. The company also highlighted its leadership in a recent BioMedWire podcast where Anthony Durkacz, the executive co‑chair, discussed strategic priorities. Additionally, its licensee Unbuzzd Wellness announced a new CEO, Michael Zapolin, as it moves forward with an alcohol metabolism accelerant.